Repurposed floxacins targeting RSK4 prevent chemoresistance and metastasis in lung and bladder cancer

作者：Stelios Chrysostomou, Rajat Roy, Filippo Prischi, Lucksamon Thamlikitkul, Kathryn Chapman, Uwais Mufti, Robert L. Peach, Laifeng Ding, David C. Hancock, Christopher Moore, Míriam Molina‐Arcas, Francesco Mauri, David J. Pinato, Joel Abrahams, Silvia Ottaviani, Leandro Castellano, Georgios Giamas, Jennifer Pascoe, Devmini C. Moonamale, Sarah Pirrie, Claire Gaunt, Lucinda Billingham, Neil Steven, Michael Cullen, David Hrouda, Mathias Winkler, John Post, Philip Cohen, Seth J. Salpeter, Vered Bar, Adi Zundelevich, Shay Golan, Dan Leibovici, Romain Lara, David R. Klug, Sophia N. Yaliraki, Mauricio Barahona, Yulan Wang, Julian Downward, Mark Skehel, Maruf M. U. Ali, Michael J. Seckl, Olivier E. Pardo · 发表于：Science Translational Medicine · 年份：2021 · DOI：10.1126/scitranslmed.aba4627 · 被引用次数：37 · 研究领域：Cancer Mechanisms and Therapy、Cancer therapeutics and mechanisms、Melanoma and MAPK Pathways

= 0.048) long-term overall survival times. Hence, we suggest that RSK4 inhibition may represent an effective therapeutic strategy for treating lung and bladder cancer.